biozone pharmaceuticals inc
(BZNE:OTC BB)
biozone pharmaceuticals inc (BZNE) Snapshot
|
Open
$0.50
|
Previous Close
$0.50
|
|
|
Day High
$0.50
|
Day Low
$0.50
|
|
|
52 Week High
01/2/13 - $3.75
|
52 Week Low
05/3/13 - $0.21
|
|
|
Market Cap
31.7M
|
Average Volume 10 Days
270.3
|
|
|
EPS TTM
--
|
Shares Outstanding
63.5M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
biozone pharmaceuticals inc (BZNE) Related Businessweek News
No Related Businessweek News Foundbiozone pharmaceuticals inc (BZNE) Details
Biozone Pharmaceuticals, Inc., through its subsidiaries, engages in developing and manufacturing over the counter (OTC) drug products, and cosmetic and beauty products on behalf of third parties in the United States and internationally. Its OTC products include hair conditioners and shampoos for treatment of eczema and psoriasis; external analgesics; skin protectants; anti-fungal products; topical anesthetics; nasal sprays; wound care products; acne products; cough and cold products; anti-itch products; and skin lightening products. The company’s cosmetic and beauty products comprise AHA and Beta Hydroxy products, instant firming serums, anti-aging products, body lotions, eye creams, moisture creams and lotions, facial scrubs, and facial masks. It also manufactures and sells dietary supplements, including vitamins, minerals, and herbal remedies. In addition, the company manufactures and sells two proprietary brands of skin care products, Glyderm and Baker Cummins, to national wholesalers; and e-commerce retailers, such as Drugstore.com and Skinstore.com. Further, it sells raw materials containing QuSomes, its proprietary delivery agents to the manufacturers of OTC drugs and cosmetics in the United States, as well as licenses the right to use QuSomes to OTC manufacturers. Biozone Pharmaceuticals, Inc. is headquartered in Englewood Cliffs, New Jersey.
Last Reported Date: 04/1/13
biozone pharmaceuticals inc (BZNE) Top Compensated Officers
biozone pharmaceuticals inc (BZNE) Key Developments
Biozone Pharmaceuticals, Inc. filed its 10-K on Apr 01, 2013 for the period ending Dec 31, 2012. In this report its auditor, Paritz & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
On 03/18/2013, Biozone Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
On 05/15/2012, Biozone Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

| Recently Viewed | |||
| BZNE:US | $0.50 USD | 0.00 | |
| Company | Last | Change |
| Perrigo Co | $120.09 USD | -1.07 |
| View Industry Companies | ||
Industry Analysis
BZNE
Industry Average
| Valuation | BZNE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 2.0x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.8x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact BIOZONE PHARMACEUTICALS INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








